SCHEMBL509203

SCHEMBL509203

CCCCC=CCCCCC(=O)O[C@@H]1[C@@H](O)[C@@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)O[C@H](CO)[C@H]1O

nearest known ligand 0.50

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
TLR4 O00206 4/20 0.50
LGALS8 O00214 2/20 0.46
CETP P11597 1/20 0.44
SELP P16109 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2959758 0.97 TLR4 (0.54) TLR4CETPSELP
SCHEMBL7532142 0.94 TLR4 (0.56) TLR4CETPSELP
SCHEMBL2959757 0.90 TLR4 (0.54) TLR4CETPSELP
SCHEMBL4185270 0.90 LGALS8 (0.50) TLR4LGALS8
SCHEMBL3393533 0.90 LGALS8 (0.50) TLR4LGALS8
SCHEMBL4181285 0.90 LGALS8 (0.50) TLR4LGALS8
SCHEMBL4199470 0.90 LGALS8 (0.50) TLR4LGALS8
SCHEMBL3388849 0.90 LGALS8 (0.50) TLR4LGALS8
SCHEMBL4185394 0.90 LGALS8 (0.50) TLR4LGALS8
SCHEMBL4193271 0.90 TLR4 (0.49) TLR4LGALS8SELP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023205439-A2 SKIN BARRIER PROTECTIVE DELIVERY SYSTEMS AND METHODS THEREOF BOBO LABS INC. (US) 2023-10-26 WO disclosed
US-20230024972-A1 BAKUCHINOYL RETINOATE AND METHODS OF USE THEREOF PHYTO TECH CORP D/B/A/ BLUE CALIFORNIA CO (US) 2023-01-26 US disclosed
WO-2022266493-A1 BAKUCHINOYL RETINOATE AND METHODS OF USE THEREOF PHYTO TECH CORP D/B/A/ BLUE CALIFORNIA CO (US) 2022-12-22 WO disclosed
US-20200261580-A1 Photodynamic Therapy Method for Skin Disorders DUSA PHARMACEUTICALS, INC. 2020-08-20 US disclosed
EP-2379082-B1 ACNE TREATMENT POWDER FOUNDATION EI INC (US) 2016-02-10 EP disclosed
US-9125919-B2 Acne treatment powder foundation EI LLC (US) 2015-09-08 US disclosed
US-20150119369-A1 Clear, Greaseless Compositions CHEMSIL SILICONES INC (US) 2015-04-30 US disclosed
US-8900607-B1 Clear, greaseless skin-care compositions CHEMSIL SILICONES, INC. (US) 2014-12-02 US disclosed
US-8852615-B1 Clear, greaseless skin-care compositions CHEMSIL SILICONES, INC. (US) 2014-10-07 US disclosed
US-20140018328-A1 Clear, Greaseless Skin Care Compositions CHEMSIL SILICONES, INC. (US) 2014-01-16 US disclosed
WO-2001002028-A2 PRE-FORMED, SHEET DEVICES SUITABLE FOR TOPICAL APPLICATION THE PROCTER & GAMBLE COMPANY (US) 2001-01-11 WO disclosed
WO-2001001933-A2 PRE-FORMED, SELF-ADHESIVE SHEET DEVICES SUITABLE FOR TOPICAL APPLICATION THE PROCTER & GAMBLE COMPANY (US) 2001-01-11 WO disclosed
WO-2001001950-A1 PRE-FORMED GEL SHEET THE PROCTER & GAMBLE COMPANY (US) 2001-01-11 WO disclosed
WO-2001002477-A1 PRE-FORMED, SELF-ADHESIVE SHEETS SUITABLE FOR TOPICAL APPLICATION THE PROCTER & GAMBLE COMPANY (US) 2001-01-11 WO disclosed
WO-2001001951-A1 SHEET-LIKE DEVICES THE PROCTER & GAMBLE COMPANY (US) 2001-01-11 WO disclosed
WO-2001001952-A1 DEVICES THE PROCTER & GAMBLE COMPANY (US) 2001-01-11 WO disclosed
US-6153208-A A WATER INSOLUBLE SUBSTRATE HAVING A SEPARATE CLEANSING AND CONDITIONING PORTIONS WITH DIFFERENT WET EXTENSIBLE, A LATHERING SURFACTANT; DRY WASHCLOTH THE PROCTER & GAMBLE COMPANY (US) 2000-11-28 US disclosed
EP-1011630-A1 CLEANSING AND CONDITIONING ARTICLE FOR SKIN OR HAIR THE PROCTER & GAMBLE COMPANY (US) 2000-06-28 EP disclosed
WO-1999055303-A1 CLEANSING ARTICLES FOR SKIN AND/OR HAIR WHICH ALSO DEPOSITS SKIN CARE ACTIVES THE PROCTER & GAMBLE COMPANY (US) 1999-11-04 WO disclosed
WO-1999013861-A1 CLEANSING AND CONDITIONING ARTICLE FOR SKIN OR HAIR THE PROCTER & GAMBLE COMPANY (US) 1999-03-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230024972-A1 BAKUCHINOYL RETINOATE AND METHODS OF USE THEREOF RBP4, RARA, RARB TLR4 3949/4885LGALS8 1485/4885CETP 1459/4885
US-20200261580-A1 Photodynamic Therapy Method for Skin Disorders ALAD, KRT18, DHPS TLR4 3539/4885LGALS8 4249/4885CETP 1685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.